Lung Cancer Staging

Proteomics

David H. Harpole*, Shari L. Meyerson

*Corresponding author for this work

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The results of ACOSOG Z4031 may provide landmark information for the use of proteomic profiling to diagnose lung cancer noninvasively and to provide more accurate predictions of survival. Although the technological developments allowing generalized use of proteomic and genomic analyses are relatively recent, major progress in understanding the molecular basis of lung cancer has been made [28]. Predicting survival is only the first step in the use of proteomics. If a reliable protein profile can be identified that is associated with poor prognosis, these proteins can then be identified and become therapeutic targets. It is not difficult to envision a day when a simple blood test will diagnose a lung cancer, perhaps even before it is clinically apparent, and, at the same time, identify the chemotherapeutic agents to which the tumor is sensitive, allowing individually directed treatment.

Original languageEnglish (US)
Pages (from-to)339-343
Number of pages5
JournalThoracic Surgery Clinics
Volume16
Issue number4
DOIs
StatePublished - Nov 1 2006

Fingerprint

Neoplasm Staging
Proteomics
Lung Neoplasms
Hematologic Tests
Proteins
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Harpole, David H. ; Meyerson, Shari L. / Lung Cancer Staging : Proteomics. In: Thoracic Surgery Clinics. 2006 ; Vol. 16, No. 4. pp. 339-343.
@article{0df8d42b30ee49c59c1c6c6534e7d69b,
title = "Lung Cancer Staging: Proteomics",
abstract = "The results of ACOSOG Z4031 may provide landmark information for the use of proteomic profiling to diagnose lung cancer noninvasively and to provide more accurate predictions of survival. Although the technological developments allowing generalized use of proteomic and genomic analyses are relatively recent, major progress in understanding the molecular basis of lung cancer has been made [28]. Predicting survival is only the first step in the use of proteomics. If a reliable protein profile can be identified that is associated with poor prognosis, these proteins can then be identified and become therapeutic targets. It is not difficult to envision a day when a simple blood test will diagnose a lung cancer, perhaps even before it is clinically apparent, and, at the same time, identify the chemotherapeutic agents to which the tumor is sensitive, allowing individually directed treatment.",
author = "Harpole, {David H.} and Meyerson, {Shari L.}",
year = "2006",
month = "11",
day = "1",
doi = "10.1016/j.thorsurg.2006.10.001",
language = "English (US)",
volume = "16",
pages = "339--343",
journal = "Thoracic Surgery Clinics",
issn = "1547-4127",
publisher = "W.B. Saunders Ltd",
number = "4",

}

Harpole, DH & Meyerson, SL 2006, 'Lung Cancer Staging: Proteomics', Thoracic Surgery Clinics, vol. 16, no. 4, pp. 339-343. https://doi.org/10.1016/j.thorsurg.2006.10.001

Lung Cancer Staging : Proteomics. / Harpole, David H.; Meyerson, Shari L.

In: Thoracic Surgery Clinics, Vol. 16, No. 4, 01.11.2006, p. 339-343.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Lung Cancer Staging

T2 - Proteomics

AU - Harpole, David H.

AU - Meyerson, Shari L.

PY - 2006/11/1

Y1 - 2006/11/1

N2 - The results of ACOSOG Z4031 may provide landmark information for the use of proteomic profiling to diagnose lung cancer noninvasively and to provide more accurate predictions of survival. Although the technological developments allowing generalized use of proteomic and genomic analyses are relatively recent, major progress in understanding the molecular basis of lung cancer has been made [28]. Predicting survival is only the first step in the use of proteomics. If a reliable protein profile can be identified that is associated with poor prognosis, these proteins can then be identified and become therapeutic targets. It is not difficult to envision a day when a simple blood test will diagnose a lung cancer, perhaps even before it is clinically apparent, and, at the same time, identify the chemotherapeutic agents to which the tumor is sensitive, allowing individually directed treatment.

AB - The results of ACOSOG Z4031 may provide landmark information for the use of proteomic profiling to diagnose lung cancer noninvasively and to provide more accurate predictions of survival. Although the technological developments allowing generalized use of proteomic and genomic analyses are relatively recent, major progress in understanding the molecular basis of lung cancer has been made [28]. Predicting survival is only the first step in the use of proteomics. If a reliable protein profile can be identified that is associated with poor prognosis, these proteins can then be identified and become therapeutic targets. It is not difficult to envision a day when a simple blood test will diagnose a lung cancer, perhaps even before it is clinically apparent, and, at the same time, identify the chemotherapeutic agents to which the tumor is sensitive, allowing individually directed treatment.

UR - http://www.scopus.com/inward/record.url?scp=37849189129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849189129&partnerID=8YFLogxK

U2 - 10.1016/j.thorsurg.2006.10.001

DO - 10.1016/j.thorsurg.2006.10.001

M3 - Review article

VL - 16

SP - 339

EP - 343

JO - Thoracic Surgery Clinics

JF - Thoracic Surgery Clinics

SN - 1547-4127

IS - 4

ER -